Members of Congress are in an unusual position as they demand an explanation for Mylan's 400 percent price hike for the EpiPen and focus attention squarely on its CEO: Heather Bresch. If lawmakers follow the usual script, Bresch could get called up to Capitol Hill next month to explain her company's...